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Abstract
Introduction: Hippocampal neuroanatomy is affected by genetic variations in dopaminergic candidate genes
and environmental insults, such as early onset of chronic cannabis exposure. Here, we examine how hippocam-
pal total and subregional volumes are affected by cannabis use and functional polymorphisms of dopamine-
relevant genes, including the catechol-O-methyltransferase (COMT), dopamine transporter (DAT1), and the
brain-derived neurotrophic factor (BDNF) genes.
Material and Methods: We manually traced total hippocampal volumes and automatically segmented hippo-
campal subregions using high-resolution MRI images, and performed COMT, DAT1, and BDNF genotyping in 59
male Caucasian young adults aged 18–30 years. These included 30 chronic cannabis users with early-onset (reg-
ular use at <16 years) and 29 age-, education-, and intelligence-matched controls.
Results: Cannabis use and dopaminergic gene polymorphism had both distinct and interactive effects on the hip-
pocampus. We found emerging alterations of hippocampal total and speciﬁc subregional volumes in cannabis users
relative to controls (i.e., CA1, CA2/3, and CA4), and associations between cannabis use levels and total and speciﬁc
subregional volumes. Furthermore, total hippocampal volume and the ﬁssure subregion were affected by canna-
bis·DAT1 polymorphism (i.e., 9/9R and in 10/10R alleles), reﬂecting high and low levels of dopamine availability.
Conclusion: These ﬁndings suggest that cannabis exposure alters the normal relationship between DAT1 poly-
morphism and the anatomy of total and subregional hippocampal volumes, and that speciﬁc hippocampal sub-
regions may be particularly affected.
Keywords: brain-derived neurotrophic factor; cannabis; catechol-O-methyltransferase gene; dopamine
transporter gene; hippocampal subﬁelds; hippocampus
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Introduction
Cannabis is regularly used by*23 million individuals
globally.1 Regular cannabis use may be detrimental to
the brain,2 being associated with neuropsychological,
emotional, and motivational impairments.3,4 The hip-
pocampus in particular may be especially sensitive to
the impact of heavy cannabis use, given its high con-
centration of cannabinoid receptors type 1 (CB1).
5–7
This is evidenced by neuroimaging results of dose-
dependent hippocampal volume reductions in regular
cannabis users.8–11 However, hippocampal alteration
has not been consistently observed across studies.2,12–18
Although it remains unclear why hippocampus volu-
metric reduction has not been consistently observed
in cannabis users, some evidence suggests that
noncannabis-speciﬁc vulnerability factors including
dopamine gene polymorphism may have played a
role in this heterogeneity.19,20 Importantly, dopamine
gene polymorphism may also contribute to adverse
mental health outcomes in cannabis users.21–24 Given
the rising prevalence of cannabis use, treatment seekers,
and the global trends toward decriminalization of can-
nabis products, it is vital to address the heterogeneity
in cannabis use-related effects across users, by examin-
ing the contribution of dopamine gene polymorphism
and cannabis use on hippocampal morphology.1
The neuroanatomy of the hippocampus and hippo-
campal subregions—subiculum, presubiculum, cornu
ammonis (CA) subﬁelds CA1-4, dentate gyrus (DG),
and ﬁmbria25—is affected by variation in the expres-
sion of genes implicated in dopamine regulation.26
These genes include the catechol-O-methyltransferase
(COMT) gene, the dopamine transporter (DAT1)
gene, and the brain-derived neurotrophic factor
(BDNF) gene: all of which are highly expressed within
the hippocampus.27–31 The COMT gene codes for the
enzyme that metabolizes dopamine and may present
as one of three variants (i.e., a single nucleotide poly-
morphism (SNP) at Val158Met, rs4680): val/val, val/
met, and met/met, which are associated with low, me-
dium, and high dopamine availability, respectively.32
The DAT1 gene, which is involved in dopamine trans-
port and reuptake, consists of a polymorphic 40-base
pair (bp) variable number of tandem repeats (VNTR)
in an untranslated region, and has common variants
including the 9-repeat (9/9R) and the 10-repeat allele
(10/10R) associated with high and low dopamine avail-
ability, respectively.33,34 Lastly, the BDNF gene is not only
involved in neuronal plasticity, but also in dopamine re-
ceptor expression. It may present with a SNP (Val66Met)
(rs6265), which can lead to a signiﬁcant reduction in
BDNF trafﬁcking to secretory granules and, as a result,
to reduced BDNF production in met carriers.35–37
Human neuroimaging studies show that COMT,
DAT1, and BDNF polymorphisms affect the neuroanat-
omy of the hippocampus27,28,38–43 and its subregions.44
These gene variants may further interact with cannabis
use to affect cognitive functions ascribed to the hippo-
campus (e.g., verbal and visuospatial learning).45–47
Despite the relevance of dopamine gene polymorphism
in hippocampal neuroanatomy and cannabis use, only
one study to date has examined and revealed the inﬂu-
ence of cannabis and COMT polymorphism on brain
anatomy in regular cannabis users.19 It remains unclear
whether polymorphisms in genes other than COMT,
which are linked to dopamine regulation—such as
DAT1 and BDNF—affect the volume of the hippocam-
pus and its subregions in cannabis users.
We aim to address this gap and extend on our previous
work19 by examining the combined effects of cannabis and
genetic polymorphism (i.e., DAT1, COMT, and BDNF)
on the volume of the hippocampus (quantiﬁed using a val-
idated, highly reliable hand-tracing method)48,49 and
its subregions. We hypothesized that reduced hippo-
campal (total and subregional) volumes would be ap-
parent in cannabis users versus controls,2 and in
those cannabis users carrying variants linked to
high relative to low dopamine level (i.e., COMT met
vs. val/val, DAT1 9/9R vs.10/10R, and BDNF val/val
vs. met allele carriers),41,50 as elevated extracellular
dopamine levels may mediate neurotoxic effects. We
further explored whether hippocampal volumes
would be affected by cannabis use ·COMT–DAT1
cross-products.
Materials and Methods
Participants
We recruited 59 male participants from the general
community, including 30 cannabis users and 29 con-
trols matched by age, intelligence quotient (IQ), educa-
tion, symptoms of depression, anxiety, and psychosis
(Table 1).
All participants were recruited through web page
and ﬂyers, and underwent a comprehensive telephone
interview screening on sociodemographic and sub-
stance use data. Participants’ inclusion criteria were
male gender, Caucasian ethnicity, aged 18–30 years,
IQ >90, <5 lifetime use of psychoactive substances
other than cannabis, nicotine, or alcohol. Cannabis
users were included if they started smoking before
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age 16, if they smoked >14 weekly ‘‘joints’’ for >2 years,
and if they tested positive for cannabinoids during
the urine toxicology test. Controls were included
if they smoked cannabis <15 times, did not smoke in
the past month, and if they tested negative for any illicit
drugs as ascertained by the urine toxicology test.
Exclusion criteria for all participants were (i) lifetime
Axis I, DSM-IV disorder apart from nicotine use disor-
der, or cannabis use disorder in cannabis users; (ii) pos-
itive urine toxicology return for opiates, cocaine,
amphetamines, and benzodiazepines; (iii) current psy-
choactive medications; (iv) history of chronic medical
illness or neurological conditions; (v) head trauma
with loss of consciousness >2min; (vi) left-handedness;
and (vii) uncorrected visual impairment, color blind-
ness, and hearing impairment.
Procedure
Participants underwent a detailed medical history
check, physical/neurological examinations, and urine
and hair toxicology tests through immunometric
assay kits (Instant-View, ASD, Inc., Poway, CA). The
latter corroborated self-reported substance use through
the Psychiatric Research Interview for Substance and
Mental Disorders (PRISM).51 Verbal intelligence was
assessed with the WAIS-III vocabulary subscale.52
All participants provided written informed consent
after receiving a complete description of the study,
and were ﬁnancially compensated for any incurred
cost. The study was approved by the Ethical and Clin-
ical Research Committee where the study was run
(CEIC-Parc de Salut Mar).
Genotyping
The COMT val108/158met (rs4680) and BDNF val66-
met (rs6265) SNP allelic variants were determined
using the 59 exonuclease TaqMan assay with ABI
7900HT Sequence Detection System (real time PCR)
supplied by Applied Biosystems. Primers and ﬂuorescent
probes were obtained from Applied Biosystems (Taq-
Man SNP genotyping assays: assay ID C_2255335_10
and C_11592758_10 for rs4680 and rs6265, respectively).
Reaction conditions were those described in the ABI
PRISM 7900HT user’s guide. Endpoint ﬂuorescent sig-
nals were detected on the ABI 7900, and the data
were analyzed using SDS software, version 2.3 (Applied
Biosystems).
DAT1 VNTR genotyping was performed using poly-
merase chain reaction (PCR).33 Primers used were For-
ward 5¢-FAM-TGTGGTGTAGGGAACGGCCTGAG
Table 1. Sample Sociodemographic, Substance Use
Characteristics and Total and Subregional
Hippocampus Volumes
Cannabis users Controls t/v2, p
Demographics
Age (years) 21.0 (2.3) 22.4 (3.3) 1.84, 0.07
Males (n [%]) 30 (100) 29 (100) —
Cannabis use
Duration (years) 5.7 (2.4) — —
Age onset (years)
First try 15.0 (1.1) 16.7 (2.0) 2.96, <0.05
Regular use 18.1 (2.0) — —
Joints
Daily 2.5 (1.5) — —
Past month 86.03 (56.85) — —
Past year 987.52 (679.97) — —
Lifetime
(cumulative)
5203 (4192) 5.1 (11.3) 6.68, < 0.01
Alcohol use
Age of onset (years) 15.0 (1.1) 15.7 (1.5) 2.20, <0.05
Duration (years) 5.7 (2.3) 6.2 (3.1) ns
Alcohol (units/week) 5.3 (3.8) 3.2 (2.6) 2.35, <0.05
Tobacco use
Current smokers (n) 27 (90.0) 9 (31.0) 21.6, < 0.01
Age of onset (years) 16.3 (1.5) 16.3 (2.2) ns
Duration of use (years) 4.5 (2.7) 4.9 (3.3) ns
Cigarettes
smoked daily (n)
6.0 (5.0) 2.4 (5.9) 1.79, 0.08
Hippocampus
Total volume 4817.6 (482.0) 4919.7 (465.6) a
Subiculum 10700.4 (879.8) 10341.6 (1076.2) a
Presubiculum 7284.6 (549.0) 7246.0 (753.8) a
CA1 5566.9 (569.5) 5243.3 (629.8) a
CA2/3 16852.4 (1653.7) 15595.6 (1779.7) a
CA4/DG 9385.2 (922.8) 8821.4 (1024.0) a
Fimbria 993.2 (219.2) 1123.6 (262.7) a
Fissure 552.5 (193.34) 537.8 (164.0) a
Genetic polymorphism
BDNF (n)
Met 10 9 ns
Val/val 16 18
COMT (n)
Met 23 22 ns
Val/val 7 7
DAT (n)
9/9R 15 13 ns
10/10R 13 16
COMT·DAT (n)
Val/val + 10/10R 4 3 ns
Met + 10/10R and
Val/val +9/9R
10 17
Met + 9/9R 14 9
Met + 10/10R and
Val/val +9/9R
10 17
Met + 9/9R 14 9
For all analyses, df= 58. COMT= Val108/158; DAT1=DAT 3¢ UTR VNTR;
BDNF= Val66Met; Met= carriers of COMT or BDNF alleles val/met and
met/met.
aResults from multiple analyses are outlined in the article body for
total hippocampal volume, and Supplementary Table S1 for hippocam-
pal subregions.
CA, cornu ammonis; DG, dentate gyrus; BDNF, brain-derived neurotro-
phic factor; COMT, catechol-O-methyltransferase; ns, not signiﬁcant;
VNTR, variable number of tandem repeats; UTR, untranslated region.
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and reverse 5¢-CTTCCTGGAGGTCACGGCTCAAGG.
Each reaction mixture contained (i) one PCR ampliﬁca-
tion buffer and 0.3 PCR enhancer solution (Invitrogen,
Carlsbad, CA), (ii) 3mM MgSO4, 200mM dNTPs,
0.2mM of each primer, (iii) 1U of Taq DNA polymer-
ase (Invitrogen), and (iv) 50 ng of genomic DNA as tem-
plate. Ampliﬁcation conditions included an initial
denaturation step of 5min at 95C, followed by 35 cycles
of 30 sec at 95C, 40 sec at 58C, 45 sec at 72C, and
5min at 72C. We used a total reaction volume of
10lL. After PCR, we detected the products of allelic-
speciﬁc ampliﬁcations (allele 9/9R, 450 bp, and allele
10/10R, 480 bp) through an automatic ABI 3730XL cap-
illary sequencer. Data were analyzed through GeneMap-
per Software v3.5 (Applied Biosystems). Sequences for
genotyping BDNF are described in detail elsewhere.53
After genotype determination, the sample was divided
into subgroups based on (i) COMT polymorphism (i.e.,
val/val homozygote andmet-allele carriers including val/
met and met homozygous); (ii) DAT1 polymorphism
(i.e., 9/9R and 10/10R allele carriers); (iii) BDNF poly-
morphism (i.e., val/val homozygote andmet-allele carri-
ers including val/met and met homozygous); and (iv)
combinations of DAT1–COMT variants associated
with different dopamine availability levels (Table 1).54–56
The distribution of COMT, DAT1, BDNF, and COMT–
DAT1 genetic polymorphism was in Hardy–Weinberg
equilibrium.
MRI data
MRI images were acquired with a 1.5T Signa Excite sys-
tem (General Electric, Milwaukee, WI) equipped with
an eight-channel phased-array head coil. High-resolution
T1-weighted anatomical images were obtained by using
a three-dimensional fast spoiled gradient inversion-
recovery prepared sequence with 130 contiguous slices
(TR, 11.8msec; TE, 4.2msec; ﬂip angle, 15; ﬁeld of
view, 30 cm; pixel matrix, 256·256; and slice thickness,
1.2mm).
Images were transferred to a Linux workstation for
preprocessing including reorientation, resizing to
1 · 1· 1mm resolution, and alignment to the Montre´al
Neurological Institute standard template (www.fmrib
.ox.ac.uk/fsl). The same investigator (A.B.) manually
delineated the hippocampus using Analyze software
(version 9.0; Mayo Clinic, Rochester, MN), while being
blind to group membership. Tracing was performed
on coronally displayed MRI slices, from the caudal to
the rostral portion of the brain, based on a previously
validated protocol.48,57 Hippocampal boundaries were
set, medially, by the cerebral spinal ﬂuid (CSF) of the
uncal cistern; laterally, by the CSF in the temporal horn
of the lateral ventricle; and inferiorly by the para-
hippocampal white matter running medially from
the temporal horn of the lateral ventricle. We used the
protocol developed by Watson et al. to separate the
hippocampus from the amygdala.58
Intraclass correlation coefﬁcients (absolute agree-
ment) were computed to assess tracing reliability,
based on 10 randomly selected images. Intrarater reli-
ability was 0.96 and 0.95, whereas inter-rater reliability
against an experienced hippocampus tracer (V.L.) was
0.94 and 0.90, for the right and left hemisphere, respec-
tively.We obtained intracranial volumes (ICVs) through
the Voxel Brain Morphometry module (http://dbm
.neuro.uni-jena.de/vbm/)59 of the Statistical Parametric
Mapping software (www.ﬁl.ion.ucl.ac.uk/spm/).
To assess hippocampal subregional effect, the hippo-
campus was also segmented using the FreeSurfer image
analysis environment (http://surfer.nmr.mgh.harvard
.edu/) version 5.3.0, into several subregions (i.e., ﬁm-
bria, presubiculum, subiculum, CA1, CA2/3, CA4/DG
ﬁelds, and hippocampus ﬁssure).25
Statistical analyses
We ran a series of four repeated-measures analysis of
covariances, with total and subregional hippocampal
volumes as dependent variables, hemisphere (i.e., left
and right) as repeated measure, and ICV as covariate.
Factors in the ﬁrst three models included COMT ge-
netic polymorphisms (i.e., val/val vs. met), DAT1 ge-
netic polymorphisms (9/9R vs. 10/10R), and BDNF
genetic polymorphisms (val/val vs. met carriers includ-
ing mostly val/met carriers and threemet/met carriers),
respectively, as well as cannabis use (i.e., user vs. non-
user). Factors in the exploratory model were cannabis
use · cross-product of COMT–DAT1 genotypes asso-
ciated with varying levels of dopamine availability54:
(i) low dopamine, including carriers of alleles val/val
and 10/10R; (ii) high dopamine, including carriers of
met and 9/9R; (iii) medium dopamine, including carri-
ers of alleles (a) val/val and 9/9R and (b) met and 10/
10R and one cannabis using carrier of the val/val and
9/9R. In addition, we explored the impact of cannabis
use as the only factor (without genetic polymorphism
as a factor) on hippocampal volumes, using the same
model already outlined.
Nicotine use (monthly cigarettes) and alcohol use
were not included as covariate in the analyses. Monthly
cigarettes were not associated with hippocampal volumes
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in cannabis users. Nine controls were tobacco smokers,
from whom only two smoked >10 cigarettes per day.
Alcohol use did not affect any analyses, at either a signif-
icant or trend level, when used as a covariate.
Finally, we ran partial correlations to explore the asso-
ciation between hippocampal total and subregional vol-
umes and cannabis use levels (lifetime, past year, and
past month cumulative number of joints) and monthly
cigarettes, controlling for ICV. No outlier was observed
in hippocampal volume distribution. All analyses were
performed using SPSS version 19.0. For all the analyses,
the signiﬁcance threshold was p< 0.05.
Discussion
Cannabis use and dopaminergic gene polymorphism
were found to have both distinct and interactive effects
on total and subregional hippocampal volumes. The
left hippocampus volume was nonsigniﬁcantly reduced
in cannabis users relative to controls (F52 = 3.70,
p = 0.06). This trend emerged when cannabis use was
the only factor in the model, and dissipated when ge-
netic polymorphism was added as an additional factor
(COMT, DAT1, BDNF, and COMT·DAT1 cross-
products, see Supplementary Table S1). Interestingly,
cannabis-using samples from past studies, with con-
sumption levels similar to those of this study (i.e.,
mean 15 years age of onset, smoking 22 days/month,
3 years duration), also show nonsigniﬁcant hippocam-
pal differences relative to nonusing controls.12 In con-
trast, samples of heavier users with longer periods of
use (i.e., daily use for >10 years)10,60 show hippocampal
reductions relative to nonusers. Duration of heavy use
may have played a role in the discrepancy of these ﬁnd-
ings, with longer duration of heavy use driving reduced
hippocampi.2,10,12,60,61 This is unsurprising given the
direct association between cannabinoid exposure and re-
ceptor organization on the hippocampus.62 A longer du-
ration of heavy cannabis use may be required, before
signiﬁcant hippocampal reduction is observed. Accord-
ingly, in this sample we found an association between
smaller total hippocampal volumes and higher cumula-
tive cannabis joints smoked during users’ lifetime
(r=0.41, p= 0.046), past year (r=0.35, p= 0.08),
and past month (r= 0.34, p= 0.08), suggesting a dose-
dependent relationship between cannabis use and hip-
pocampal volume.
We also found signiﬁcant effects of cannabis on spe-
ciﬁc subregions, with a larger volume in CA1 (i.e., in two
of the four analyses, which used COMT and DAT1 as
factors), CA2/3, and CA4 (i.e., in one analysis using
COMT and cannabis as factors) in cannabis users rel-
ative to nonusers, when controlling for COMT gene
polymorphism and ICV (Supplementary Table S1);
this is alongside dose-dependent relationships be-
tween the volume of various subregions and cannabis
use levels—including larger right CA1 and greater
monthly/yearly joints (r53= 0.29, p< 0.05 and r53= 0.25,
p= 0.07), larger right CA2/3 and greater monthly/year-
ly/lifetime joints (r53= 40, p< 0.005, r53= 0.36, p< 0.01
and r53= 0.33, p< 0.05), and larger right CA4 and greater
monthly, yearly, and lifetime joints (r53= 0.30, p< 0.05,
r53= 0.26, p= 0.06 and r53= 0.23, p= 0.09).
Total hippocampal volume and the ﬁssure subregion
were affected by cannabis ·DAT1 polymorphism (i.e.,
9/9R and in 10/10R alleles), reﬂecting high and low levels
of dopamine availability (F1,52= 4.93, p= 0.031, see Fig. 1).
Across all groups, average hippocampal volume
was largest in control carriers of the 10/10R allele,
FIG. 1. Hippocampal volumes by DAT1
polymorphism variants (10/10R and 9/9R) in
controls (HC) and cannabis users (CB), with larger
volumes in HC 10/10R carriers relative to CB
10/10R and CB 9/9R carriers; smaller volumes in
HC 9/9R carriers versus CB 9/9R carriers and HC
10/10R carriers.
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followed by cannabis-using carriers of the 9/9R and the
10/10R allele, and ﬁnally by control carriers of the 9/9R
allele. 10/10R-carrying cannabis users had signiﬁcantly
smaller hippocampi than 10/10R-carrying controls in
the left hemisphere (t27 = 7.81, p< 0.001, Cohen’d
r =0.8, large effect size) and right hemisphere
(t26 = 4.07, p < 0.0001; Cohen’d r =0.7, large effect
size). However, the inverse pattern was observed in
9/9R carriers, with 9/9R-carrying cannabis users having
larger left hippocampal volumes than 9/9R-carrying
controls (t26 = 4.07, p < 0.0001, Cohen’d r=0.6, large
effect size). This may be related to the DAT1 genotype
affecting total hippocampal volumes in controls (i.e.,
9/9R and 10/10R carriers showed the smallest and larg-
est volumes, respectively—left: t27 = 2.69, p = 0.012 and
right t27 = 1.28, p = 0.21), but not in cannabis users (i.e.,
9/9R and 10/10R carriers had similar hippocampal vol-
umes—left, t26 = 0.68, p= 0.50 and right, t26 = 0.26,
p= 0.79). Notably, the cannabis·DAT1 effect on total
hippocampal volumes may be driven by speciﬁc subre-
gion (i.e., hippocampal ﬁssure, Supplementary Table S1)
where this effect was also observed. The interaction be-
tween dopamine genetic polymorphism (DAT1) and
cannabis may partly explain the mixed evidence to
date on smaller hippocampal volumes in cannabis
users than in controls. This notion remains unex-
plored, as genetic polymorphism remains underinvesti-
gated in neuroimaging studies of cannabis users.2
Our ﬁndings suggest that carrying the 9/9R allele of
DAT1 predates smaller hippocampi, and cannabis use
may reverse this process. Although the underlying
mechanism remains unclear, we speculate that canna-
bis exposure may selectively interact with DAT1 gene
variants to alter the normal effect of dopaminergic
transmission on neuroanatomy.63–65 Chronic cannabis
use may alter ‘‘optimal’’ extracellular dopamine levels
(e.g., lower synthesis/release and/or contributing to hy-
persensitivity of postsynaptic receptors)66 and compro-
mise neuronal growth.67 The DAT1 gene inﬂuences
neuronal growth, survival, and differentiation, and is
furthermore highly expressed within the hippo-
campus.67,68 Importantly, emerging evidence shows
that dopaminergic genes (e.g., DAT1)63,69 mediate
the effects of speciﬁc cannabinoid compounds on
the brain. It remains unclear whether these effects
change for distinct cannabinoid compounds that
have very different effects on neuroanatomy,2,70 neu-
ral activity,71 and emotion processing72—such as the
neuroprotective cannabidiol73,74 and the psychoto-
genic tetrahydrocannabinol.75
Apart from the interactive effect of cannabis ·DAT1
on hippocampal ﬁssure volume, the total and subregional
volumes of the hippocampus were not affected by either
COMT, DAT1, or BDNF polymorphism alone, nor by
cannabis ·COMT or cannabis ·BDNF interaction.
This is consistent with some38,76,77 but not other ﬁnd-
ings to date that demonstrated an effect of COMT
(i.e., volume reduction in val vs. met allele carri-
ers)28,50 and BDNF (i.e., volume reduction in met vs.
val allele carriers).41 We may have failed to detect
an effect of COMT, DAT1, or BDNF polymorphism
due to the small sample size, or the relatively lower
duration of heavy cannabis use in our user sample.
Yet, our ﬁndings suggest that neuroanatomy may be
affected by a multitude of genetic and environmental
(e.g., substance use) factors.
Our third exploratory analysis suggests that the vol-
ume of the hippocampus is affected by COMT–DAT1
combinations associated with different levels of dopa-
mine concentration. Hippocampal volumes were (at a
trend level) affected by cannabis ·COMT–DAT1
cross-products (F2,50 = 2.62, p = 0.08) and signiﬁ-
cantly affected by the cross-product of hemisphere·
cannabis·COMT–DAT1 (F2= 3.62, p= 0.034). Interest-
ingly, the analysis on COMT–DAT1 products linked to
different levels of dopamine availability revealed that
the volume of the left hippocampus was the largest
within controls, but not cannabis users, who carried
alleles linked to high versus low and medium dopa-
mine level. Similarly, other reports show that regional
brain volumes (i.e., within the caudate)78 and activ-
ity45,54,55,79 are affected by the epistasis between
dopamine-related genes. We warrant the conduct of
studies to examine the role of gene · gene interac-
tion on dopamine availability and neuroanatomy
in large normative samples, including cannabis
users.55 Finally, in this model, hippocampal volumes
were not affected by cannabis alone (F1,50= 0.82, p= 0.37)
and COMT–DAT1 cross-products (F2,50 = 0.2.29,
p = 0.11).
Interestingly, we found emerging effects for larger
subregional volumes in cannabis users. These ef-
fects are surprising given the signiﬁcant evidence for
dose-dependent total hippocampal volume reduc-
tion, and subregional volume reduction in cannabis
users.2,10,80,81 This discrepancy may be due to the dif-
ferent method of delineating the total hippocampus
(i.e., manual tracing) and its subregions (i.e., automated
segmentation). Automated segmentation methods may
be more susceptible to magnetic resonance image quality
Batalla, et al.; Cannabis and Cannabinoid Research 2018, 3.1
http://online.liebertpub.com/doi/10.1089/can.2017.0021
6
factors.82 Our magnetic resonance images presented with
artifacts along the temporal lobe, which may have re-
duced the accuracy of automated segmentations. Alterna-
tively, cannabis may have differential effects in distinct
subregions of the hippocampus, given the different distri-
bution of cannabinoid receptors across subregions.83
In our study, total hippocampal reduction in can-
nabis users relative to controls is presented in the
left hemisphere, whereas subregional volume enlarge-
ment in cannabis users relative to controls is pre-
sented in the right hemisphere, which may point to
a hemisphere-speciﬁc effect as well. Importantly, the
ﬁnding of larger subregions in cannabis users was in-
consistently found across the series of four statistical
analyses examining the effect of cannabis and four
distinct genetic polymorphisms (COMT, DAT1,
BDFN, and COMT ·DAT1 cross-products) on the
hippocampus. Of the four analyses, larger CA2/3 sub-
regions were detected in only two analyses, and larger
CA2 and CA4 were apparent in only one analysis
(Supplementary Table S1). The inconsistent ﬁndings
on larger hippocampal subregions must be interpreted
with caution and warrant replication in a separate
sample of regular cannabis users.
This study has several limitations. Our small sam-
ple size of 59 participants limited the power to detect
complex effects of COMT, DAT1, and cannabis. Still,
large effect sizes in the cannabis ·DAT1 effects on
hippocampal volumes (i.e., r = 0.6 and r = 0.8) warrant
replication in large normative cohorts, where the
impact of additional genetic polymorphism relevant
to neuroanatomy can be measured with adequate
power—including cannabis receptor-1 (CNR1)43 and
P2 promoter region (rs2097603).28 Such work is war-
ranted to unravel the complex gene–environmental
interplay that affects neuroanatomical alterations
in cannabis users. Using Bonferroni correction for
multiple comparison, we used a stringent signiﬁ-
cance threshold p < 0.01 (to control for the four in-
dependent variables used to predict hippocampal
volumes—COMT, DAT1, BDNF, and COMT–DAT1)
and found that only sparse results survived (i.e., canna-
bis·COMT–DAT1, and cannabis·hemisphere on the
ﬁssure).
Furthermore, although we have only considered the
effect of cannabis use and genetic polymorphism on
hippocampus volume, genetic predisposition may
similarly interact with cannabis use to affect the neu-
roanatomy of other subcortical structures (e.g., ven-
tral striatum),84 and should be considered in future
studies. Finally, we could not discern the impact
of nicotine from that of cannabis on hippocampal
volumes.85 Although we found no signiﬁcant correla-
tion between total hippocampal volumes and monthly
cigarettes smoked, we cannot conclusively rule out the
effect of nicotine on hippocampal volumes, given the
low level of cigarette use in our participant sample
(average of <7 cigarettes daily).
Conclusions
Our ﬁndings suggest that although cannabis alone may
subtly affect hippocampal neuroanatomy, given the
trend-level and dose-dependent reduction observed in
cannabis users, the interaction between cannabis and
DAT1 polymorphism was a stronger predictor of hip-
pocampal volume differences between cannabis users
and controls. Hippocampal neuroanatomical differ-
ences were observable between DAT1 9/9R and 10/
10R-carrying controls but not in cannabis users in
our sample, suggesting that cannabinoid exposure
may alter the normal relationship between DAT1 poly-
morphism and hippocampal neuroanatomy. The in-
creasing potency of cannabis, rates of treatment-
seeking users, and availability of cannabis products
due to recent decriminalization policies warrant the
identiﬁcation of vulnerability factors within cannabis
users for adverse neurobiological outcomes, such that
targeted prevention and intervention strategies may
be developed. We warrant the examination of large-
scale adult and adolescent samples from existing con-
sortia collating genetic, neural, and behavioral data
(ENIGMA Addiction http://enigma.ini.usc.edu/ongoing/
enigma-addiction-working-group/86 and IMAGEN
http://imagen-europe.com/en/consortium.php)87 to
study the role of additional genetic polymorphisms (e.g.,
CNR1) and nongenetic factors on neuroanatomy (e.g.,
mental health, socioeconomic status, comorbid sub-
stance use, and cannabinoid compounds), and psycho-
social outcomes in cannabis users, and to ultimately
minimize cannabis-related harms.
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